Manning & Napier Group's VRTX Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 474,822 shares of Vertex Pharmaceuticals Incorporated (VRTX) worth $187.7 M, representing 2.39% of the portfolio. First purchased in 2016-Q2, this long-term strategic position has been held for 38 quarters.
Based on 13F filings, Manning & Napier Group has maintained a strategic position in VRTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2016, adding 1.98 M shares. Largest reduction occurred in Q3 2017, reducing 745,258 shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's Vertex Pharmaceuticals Incorporated (VRTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Vertex Pharmaceuticals Incorporated (VRTX) Trades by Manning & Napier Group
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2016 | +126,990 | New Buy | 126,990 | $86.01 |
| Q3 2016 | +15,550 | Add 12.25% | 142,540 | $87.20 |
| Q4 2016 | +1.98 M | Add 1391.53% | 2.13 M | $73.67 |
| Q1 2017 | -361,601 | Reduce 17.01% | 1.76 M | $109.35 |
| Q2 2017 | -133,293 | Reduce 7.55% | 1.63 M | $128.87 |
| Q3 2017 | -745,258 | Reduce 45.69% | 885,868 | $152.04 |
| Q4 2017 | +902,503 | Add 0.00% | 902,502 | $149.86 |
| Q1 2018 | -544,897 | Reduce 60.38% | 357,605 | $162.98 |
| Q2 2018 | +4,100 | Add 1.15% | 361,705 | $169.96 |
| Q3 2018 | -10,575 | Reduce 2.92% | 351,130 | $192.74 |
| Q4 2018 | -18,322 | Reduce 5.22% | 332,808 | $165.71 |
| Q1 2019 | -32,214 | Reduce 9.68% | 300,594 | $183.95 |
| Q2 2019 | +82,670 | Add 27.50% | 383,264 | $183.37 |
| Q3 2019 | -145,547 | Reduce 37.98% | 237,717 | $169.42 |
| Q4 2019 | -18,480 | Reduce 7.77% | 219,237 | $218.94 |
| Q1 2020 | -165,932 | Reduce 75.69% | 53,305 | $237.93 |
| Q2 2020 | +750 | Add 1.41% | 54,055 | $290.30 |
| Q3 2020 | +2,827 | Add 5.23% | 56,882 | $272.09 |
| Q4 2020 | +335,562 | Add 589.93% | 392,444 | $236.34 |
| Q1 2021 | +465,772 | Add 118.68% | 858,216 | $214.89 |
| Q2 2021 | +38,865 | Add 4.53% | 897,081 | $201.63 |
| Q3 2021 | -24,153 | Reduce 2.69% | 872,928 | $181.39 |
| Q4 2021 | +1,044 | Add 0.12% | 873,972 | $219.60 |
| Q1 2022 | -179,213 | Reduce 20.51% | 694,759 | $260.97 |
| Q2 2022 | -414,752 | Reduce 59.70% | 280,007 | $281.79 |
| Q3 2022 | -3,116 | Reduce 1.11% | 276,891 | $289.53 |
| Q4 2022 | -4,987 | Reduce 1.80% | 271,904 | $288.78 |
| Q1 2023 | -7,652 | Reduce 2.81% | 264,252 | $315.07 |
| Q2 2023 | -7,625 | Reduce 2.89% | 256,627 | $351.91 |
| Q3 2023 | -7,499 | Reduce 2.92% | 249,128 | $347.74 |
| Q4 2023 | -11,817 | Reduce 4.74% | 237,311 | $406.89 |
| Q1 2024 | -7,681 | Reduce 3.24% | 229,630 | $418.00 |
| Q2 2024 | +158,333 | Add 0.00% | 158,332 | $468.72 |
| Q3 2024 | -2,571 | Reduce 1.62% | 155,761 | $465.08 |
| Q4 2024 | -5,635 | Reduce 3.62% | 150,126 | $402.70 |
| Q1 2025 | +84,982 | Add 56.61% | 235,108 | $484.82 |
| Q2 2025 | -1,528 | Reduce 0.65% | 233,580 | $445.21 |
| Q3 2025 | +241,242 | Add 103.28% | 474,822 | $395.31 |
Manning & Napier Group's Vertex Pharmaceuticals Incorporated Investment FAQs
Manning & Napier Group first purchased Vertex Pharmaceuticals Incorporated (VRTX) in Q2 2016, acquiring 126,990 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held Vertex Pharmaceuticals Incorporated (VRTX) for 38 quarters since Q2 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group's largest addition to Vertex Pharmaceuticals Incorporated (VRTX) was in Q4 2016, adding 2,126,020 shares worth $156.62 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 474,822 shares of Vertex Pharmaceuticals Incorporated (VRTX), valued at approximately $187.7 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Vertex Pharmaceuticals Incorporated (VRTX) represents approximately 2.39% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group's peak holding in Vertex Pharmaceuticals Incorporated (VRTX) was 2,126,020 shares, as reported at the end of Q4 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.